BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 36642638)

  • 1. Performance of CellDetect for detection of bladder cancer: Comparison with urine cytology and UroVysion.
    Shefer HK; Masarwe I; Bejar J; Naamnih LH; Gueta-Milshtein K; Shalata A; Hadid Y; Nativ O; Nativ O
    Urol Oncol; 2023 Jun; 41(6):296.e1-296.e8. PubMed ID: 36642638
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Novel Urine-Based Assay for Bladder Cancer Diagnosis: Multi-Institutional Validation Study.
    Davis N; Shtabsky A; Lew S; Rona R; Leibovitch I; Nativ O; Cohen M; Mor Y; Lindner U; Glickman Y; Matzkin H; Tsivian A; Gofrit O; Yossepovitch O
    Eur Urol Focus; 2018 Apr; 4(3):388-394. PubMed ID: 28753799
    [TBL] [Abstract][Full Text] [Related]  

  • 3. What is the role of CellDetect
    Yüksel Ö; Tosun Ç; Gümrükçü G; Tokuç E; Yücebaş ÖE
    Urologia; 2023 May; 90(2):261-265. PubMed ID: 36660912
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnostic value comparison of CellDetect, fluorescent in situ hybridization (FISH), and cytology in urothelial carcinoma.
    Shang D; Liu Y; Xu X; Chen Z; Wang D
    Cancer Cell Int; 2021 Sep; 21(1):465. PubMed ID: 34488763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative evaluation of the nuclear matrix protein, fibronectin, urinary bladder cancer antigen and voided urine cytology in the detection of bladder tumors.
    Eissa S; Swellam M; Sadek M; Mourad MS; El Ahmady O; Khalifa A
    J Urol; 2002 Aug; 168(2):465-9. PubMed ID: 12131289
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of NMP22 BladderChek test and urine cytology for the detection of recurrent bladder cancer.
    Kumar A; Kumar R; Gupta NP
    Jpn J Clin Oncol; 2006 Mar; 36(3):172-5. PubMed ID: 16520358
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic value of Xpert® BC Detection, Bladder Epicheck®, Urovysion® FISH and cytology in the detection of upper urinary tract urothelial carcinoma.
    Pycha S; Trenti E; Mian C; Schwienbacher C; Hanspeter E; Palermo M; Pycha A; Danuser H; D'Elia C
    World J Urol; 2023 May; 41(5):1323-1328. PubMed ID: 36929411
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical evaluation of a multi-target fluorescent in situ hybridization assay for detection of bladder cancer.
    Sarosdy MF; Schellhammer P; Bokinsky G; Kahn P; Chao R; Yore L; Zadra J; Burzon D; Osher G; Bridge JA; Anderson S; Johansson SL; Lieber M; Soloway M; Flom K
    J Urol; 2002 Nov; 168(5):1950-4. PubMed ID: 12394683
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Urinary BTA-TRAK in the follow-up of superficial transitional-cell bladder carcinoma].
    Fernández Gómez JM; García Rodríguez J; Escaf Barmadah S; Raigoso P; Rodríguez Martínez JJ; Allende MT; Casasola Chamorro J; Rodríguez Faba O; Martín Benito JL; Regadera Sejas FJ
    Arch Esp Urol; 2002; 55(1):41-9. PubMed ID: 11957750
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overexpression of semaphorin 3A in patients with urothelial cancer.
    Vadasz Z; Rubinstein J; Bejar J; Sheffer H; Halachmi S
    Urol Oncol; 2018 Apr; 36(4):161.e1-161.e6. PubMed ID: 29288007
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multitarget fluorescence in situ hybridization assay detects transitional cell carcinoma in the majority of patients with bladder cancer and atypical or negative urine cytology.
    Skacel M; Fahmy M; Brainard JA; Pettay JD; Biscotti CV; Liou LS; Procop GW; Jones JS; Ulchaker J; Zippe CD; Tubbs RR
    J Urol; 2003 Jun; 169(6):2101-5. PubMed ID: 12771727
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic value of voided urine and bladder barbotage cytology in detecting transitional cell carcinoma of the urinary tract.
    Konety BR; Metro MJ; Melham MF; Salup RR
    Urol Int; 1999; 62(1):26-30. PubMed ID: 10436427
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Surveillance of patients with bladder carcinoma using fluorescent in-situ hybridization on bladder washings.
    Bergman J; Reznichek RC; Rajfer J
    BJU Int; 2008 Jan; 101(1):26-9. PubMed ID: 17850364
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fluorescence in situ hybridization (FISH) in the diagnosis of bladder and upper tract urothelial carcinoma: the largest single-institution experience to date.
    Gomella LG; Mann MJ; Cleary RC; Hubosky SG; Bagley DH; Thumar AB; McCue PA; Lallas CD; Trabulsi EJ
    Can J Urol; 2017 Feb; 24(1):8620-8626. PubMed ID: 28263126
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the nuclear matrix protein 22 with voided urine cytology in the diagnosis of transitional cell carcinoma of the bladder.
    Lekili M; Sener E; Demir MA; Temeltaş G; Müezzinoğlu T; Büyüksu C
    Urol Res; 2004 May; 32(2):124-8. PubMed ID: 14685796
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of diagnostic strategies for bladder cancer using computed tomography (CT) urography, flexible cystoscopy and voided urine cytology: results for 778 patients from a hospital haematuria clinic.
    Blick CG; Nazir SA; Mallett S; Turney BW; Onwu NN; Roberts IS; Crew JP; Cowan NC
    BJU Int; 2012 Jul; 110(1):84-94. PubMed ID: 22122739
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative diagnostic value of urine cytology, UBC-ELISA, and fluorescence in situ hybridization for detection of transitional cell carcinoma of urinary bladder in routine clinical practice.
    May M; Hakenberg OW; Gunia S; Pohling P; Helke C; Lübbe L; Nowack R; Siegsmund M; Hoschke B
    Urology; 2007 Sep; 70(3):449-53. PubMed ID: 17688921
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive value of MCM5 (ADXBLADDER) analysis in urine of men evaluated for the initial diagnosis of bladder cancer: A comparative prospective study.
    Anastasi E; Maggi M; Tartaglione S; Angeloni A; Gennarini G; Leoncini PP; Sperduti I; Di Lascio G; De Stefano V; Di Pierro GB; Del Giudice F; Busetto GM; De Berardinis E; Sciarra A
    Diagn Cytopathol; 2020 Nov; 48(11):1034-1040. PubMed ID: 32562513
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of DD23 as a marker for detection of recurrent transitional cell carcinoma of the bladder in patients with a history of bladder cancer.
    Gilbert SM; Veltri RW; Sawczuk A; Shabsigh A; Knowles DR; Bright S; O'Dowd GJ; Olsson CA; Benson MC; Sawczuk IS
    Urology; 2003 Mar; 61(3):539-43. PubMed ID: 12639642
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Voided urine versus bladder washing cytology for detection of urothelial carcinoma: which is better?
    Keller AK; Jensen JB
    Scand J Urol; 2017 Aug; 51(4):290-292. PubMed ID: 28398114
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.